MI-CP151 was a section 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre review To judge multiple intravenous doses of sifalimumab, in Grownup people with dermatomyositis or polymyositis (NCT00533091). Major trial objectives were To judge the security and tolerability of sifalimumab in dermatomyositis or polymyositis patients, whilst one of many exploratory... https://le-30099876.imblogs.net/80703810/the-basic-principles-of-tyrosinase-in-12